HUMAN GROWTH HORMONE RELEASING FACTOR IN LONG TERM TREATMENT OF CHILD

$17,457M01FY2000RRNIH

University Of California San Francisco, San Francisco CA

Investigators

Linked publications & trials

Paper 36653093 Paper 34853878 Paper 34059527 Paper 34004150 Paper 33972431 Paper 33944778 Paper 33938449 Paper 33924494 Paper 33903257 Paper 33898205 Paper 33888157 Paper 33865855 Paper 33798442 Paper 33796067 Paper 33793394 Paper 33758402 Paper 33753542 Paper 33749765 Paper 33741735 Paper 33723250 Paper 33680492 Paper 33652807 Paper 33649974 Paper 33631213 Paper 33539356 Paper 33531419 Paper 33502458 Paper 33479483 Paper 33440172 Paper 33404670 Paper 33326040 Paper 33284321 Paper 33278474 Paper 33242471 Paper 33216378 Paper 33074282 Paper 33010412 Paper 32998025 Paper 32970098 Paper 32878448 Paper 32750175 Paper 32682597 Paper 32421163 Paper 32416645 Paper 32339414 Paper 31234194 Paper 31021177 Paper 29890324 Paper 29724352 Paper 28918207 Paper 28817419 Paper 28060170 Paper 27862206 Paper 27444177 Paper 26902528 Paper 26885808 Paper 26097769 Paper 25582974 Paper 25488617 Paper 25407158 Paper 25306190 Paper 24685959 Paper 24598797 Paper 24354732 Paper 24079880 Paper 23771484 Paper 23599313 Paper 23537841 Paper 23508219 Paper 23452954 Paper 23439301 Paper 23349510 Paper 23339116 Paper 23339082 Paper 23319742 Paper 23216540 Paper 23175617 Paper 22669363 Paper 22383118 Paper 22269205 Paper 22188830 Paper 22167015 Paper 22127392 Paper 21949144 Paper 21554828 Paper 21422385 Paper 21350366 Paper 21307706 Paper 21276755 Paper 21249401 Paper 21150784 Paper 21129757 Paper 21036173 Paper 20740639 Paper 20708879 Paper 20696663 Paper 20638007 Paper 20634905 Paper 20610117 Paper 20547400

Abstract

The primary objective of this study is to evaluate the tolerability and efficacy of the once-a-day subcutaneous administration of GRF 1-44 during 12-24 months in stimulating growth velocity in children with documented growth hormone secretion deficiency of hypothalamic origin. This study, sponsored by ICN Pharmaceuticals, Inc, is a Phase III, single daily administration, non-randomized, open, outpatient study, with each patient serving as his/her own control. Efficacy will be assessed after 6 months based on growth rate.

View original record on NIH RePORTER →